RxDoctor Payments Data

Marc-Alain Babi, MD

Neurocritical Care · Port St Lucie, FLNPI 1831483841

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Immedica Pharma US, Inc. at 49.0% of the total. Reporting peaked in 2022 at $358 and has fallen 64.9% since, to $126 in 2025.

$812in general payments, 2019–2025

Across 9 payments — averaging $90.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Immedica Pharma US, Inc.$398
  • Boston Scientific$163
  • Microtransponder, Inc.$126
  • UCB, Inc.$101
  • EMD Serono, Inc.$25
$108,091in research payments, 2019–2025

Across 20 payments — averaging $5404.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Immedica Pharma US, Inc.$108K

What the payments were for

  • Food & beverage$812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Immedica Pharma US, Inc.5$398
Boston Scientific1$163
Microtransponder, Inc.1$126
UCB, Inc.1$101
EMD Serono, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812 in reported general payments places this provider in the 80th percentile of 36 neurocritical care providers in Florida.

See all neurocritical care providers in Florida

Medicare billing

Part B allowed, 2024
$201,101
Medicare patients
412
Services billed
1,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurocritical care in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →